J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
Potential For Post-Tagrisso Therapy Niche
Executive Summary
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
You may also be interested in...
Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout
Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.
Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.
Gilead Awaits EMA Verdict On Trodelvy As It Whizzes Through EU Review
Sponsors of six new products, including a first-in-class treatment for unresectable locally advanced or metastatic triple-negative breast cancer, will find out this week if their products are on course to be approved for use in the EU. Also, two sponsors might be asked to address last-minute questions about their drugs.